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ABSTRACT
siVirus (http://siVirus.RNAi.jp/) is a web-based online
software system that provides efficient short inter-
fering RNA (siRNA) design for antiviral RNA inter-
ference (RNAi). siVirus searches for functional,
off-target minimized siRNAs targeting highly con-
served regions of divergent viral sequences. These
siRNAs are expected to resist viral mutational
escape, since their highly conserved targets likely
contain structurally/functionally constrained ele-
ments. siVirus will be a useful tool for designing
optimal siRNAs targeting highly divergent patho-
gens, including human immunodeficiency virus
(HIV), hepatitis C virus (HCV), influenza virus and
SARS coronavirus, all of which pose enormous
threats to global human health.
INTRODUCTION
RNA interference (RNAi) is now widely used to knockdown
gene expression in a sequence-speciﬁc manner, making it a
powerful tool not only for studying gene function, but also for
therapeutic purposes, including antiviral treatments (1–4).
Currently, the replication of a wide range of viruses can be
inhibited successfully using RNAi, with both short interfering
RNAs (siRNAs) and siRNA expression vectors (5).
In mammalian RNAi, the efﬁcacy of each siRNA varies
widely depending on its sequence; only a limited fraction
of randomly designed siRNAs is highly effective. Many
experiments have been conducted to clarify possible sequence
requirements of functional siRNAs. Of these, our work incor-
porates guidelines from three major studies (6–8) of selecting
functional siRNAs. However, designing functional siRNAs
that target viral sequences is problematic because of their
extraordinarily high genetic diversity. For example, about
500 entries of near full-length sequences of HIV-1
group M, which is largely responsible for global pandemic,
are stored in the sequence databases, but it proved impossible
to select a common 21mer from among all of them. Moreover,
RNAi-resistant viral mutants achieved through point mutation
or deletion emerge rapidly when targeting viruses in cell cul-
ture. These problems suggest a strong need to select highly
conserved target sites for designing antiviral siRNAs. Further-
more, the off-target silencing effects of siRNA are also a
serious problem that could affect host gene expression (9).
Off-target silencing effects arise when an siRNA has sequence
similarities with unrelated genes. In antiviral RNAi, it is desir-
able to minimize off-target effects against human genes.
Consequently, only a limited fraction of 21mers is suitable
foruseasantiviralsiRNAs.Inthisstudy,wedevelopedanovel
web-based online software system, siVirus, which provides
functional, off-target minimized siRNAs targeting highly con-
served regions of divergent viral sequences.
METHODS
Selection of highly conserved siRNA target sites
Highlyconserved siRNA sequences are selectedbased on their
degree of conservation, deﬁned as the proportion of viral
sequences that are targeted by the corresponding siRNA,
with complete matches (i.e. 21/21 matches). All possible
siRNA candidates targeting every other position of user-
selected viral sequences are generated and their degrees of
conservation are computed. Users can arbitrarily specify a
set of viral sequences for the computation; e.g. sequences
can be selected from a speciﬁc geographic region(s) or a
speciﬁc genotype(s) to design the best siRNAs tailored to
speciﬁc user needs. siVirus also accepts user’s own sequences
in a multi-FASTA format and shows whether each siRNA can
target the posted sequences.
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In mammalian RNAi, the efﬁcacy of each siRNA varies mark-
edly depending on its sequence; hence, several groups have
reported guidelines for selecting functional siRNAs. siVirus
incorporates the guidelines of Ui-Tei et al. (6), Reynolds et al.
(7) and Amarzguioui et al. (8) and shows whether each siRNA
satisﬁes these guidelines.
Off-target searches
Off-target searches were performed for each siRNA using
siDirect (10,11). siVirus shows the number of off-target hits
within two mismatches against the non-redundant database of
human transcripts (10).
Database maintenance
Currently, siVirus incorporates viral genome sequences of
HIV-1, HCV, inﬂuenza A virus and SARS coronavirus.
These sequences were downloaded from the Los Alamos
HIV Sequence Database (http://hiv-web.lanl.gov/), the Los
Alamos HCV Sequence Database (12), the NCBI Inﬂuenza
Virus Sequence Database (http://www.ncbi.nlm.nih.gov/
genomes/FLU/FLU.html), and NCBI GenBank (13), respect-
ively. siVirus will be updated continuously as these databases
are revised. We also plan to incorporate other viruses if
sufﬁcient numbers of their sequences are available.
RESULTS AND DISCUSSION
To design anti-HIV siRNA, we analyzed the 495 near full-
length HIV-1 sequences listed in Supplementary Table 1. A
total of4417 157 possible siRNA candidates(i.e. substrings of
length 21) targeting every other position of the HIV-1
sequences were produced from the 495 viral sequences.
The analysis of these siRNA candidates revealed that highly
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(   :conserved,   :not conserved,   :sequence not available)
AGCCTCAATAAAGCTTGCCTTga 2 [detail] yes yes 97.3% (148/152)
AAGCCTCAATAAAGCTTGCCTtg [detail] 1 yes 96.0% (146/152)
TCAAAATTTTCGGGTTTATTAca [detail] 2 yes 92.8% (169/182)
ATTCAAAATTTTCGGGTTTATta [detail] 0 yes 92.3% (168/182)
TTCAAAATTTTCGGGTTTATTac [detail] 2 yes yes 92.3% (168/182)
AGGAGAGAGATGGGTGCGAGAgc [detail] 2 yes 92.1% (152/165)
GGAGGCTAGAAGGAGAGAGATgg [detail] 4 yes 91.5% (151/165)
AGCGGAGGCTAGAAGGAGAGAga [detail] 4 yes 90.9% (150/165)
GACTAGCGGAGGCTAGAAGGAga [detail] 0 yes 90.8% (149/164)
CGGAGGCTAGAAGGAGAGAGAtg [detail] 7 yes yes 90.3% (149/165)
CTAGCGGAGGCTAGAAGGAGAga [detail] 1 yes 90.2% (148/164)
TTTGACTAGCGGAGGCTAGAAgg [detail] 0 yes 89.6% (147/164)
TGCTTAAGCCTCAATAAAGCTtg [detail] 2 yes 88.2% (135/153)
CCACTGCTTAAGCCTCAATAAag [detail] 1 yes 87.5% (134/153)
AACCCACTGCTTAAGCCTCAAta [detail] 1 yes 87.1% (129/148)
ACCCACTGCTTAAGCCTCAATaa [detail] 2 yes yes yes 87.1% (129/148)
GGGGAAGTGACATAGCAGGAAct [detail] 3 yes 87.9% (160/182)
AGGGGAAGTGACATAGCAGGAac [detail] 2 yes 87.9% (160/182)
GACAGCAGTACAAATGGCAGTat [detail] 3 yes 88.4% (161/182)
CAGCAGTACAAATGGCAGTATtc [detail] 3 yes yes 87.3% (159/182)
Figure 1. (A) The degree of conservation is calculated for all possible siRNA candidates (total 4 417 157) targeting every other position of 495 HIV-1 sequences.
(B)Theefficacypredictionsofthese4417157siRNAcandidatesbasedonthreedifferentguidelines:Ui-Teietal.(6),Reynoldsetal.(7)andAmarzguiouietal.(8).
(C)TypicaloutputofsiVirusfordesigninganti-HIVsiRNAs.Sequenceinformation,efficacypredictions,off-targetsearchresultsandthedegreesofconservationare
shown.
Nucleic Acids Research, 2006, Vol. 34, Web Server issue W449conserved siRNAs constituted only 0.3% of the possible
siRNAs if >90% conservation is expected (Figure 1A). The
fraction is still as small as 0.8% even if the threshold of the
conservation is relaxed to 80%. On the other hand, siRNAs
predicted to be functional by one or more guidelines (6–8)
constituted35.5%ofthe 4417157siRNAs(Figure 1B).Taken
together, siRNAs that are >80% conserved, and satisfy at least
one guideline constitute only 0.2% of the siRNAs. In this
condition, 20–30 siRNAs can be designed for each full-length
sequence of HIV-1. These indicate that most of the randomly
designed siRNAsare notsuited fortargeting HIV-1efﬁciently.
Figure 1C shows typical output from siVirus for designing
anti-HIV siRNAs. A total of 182 sequences from HIV-1
subtypes B, C and CRF01_AE, which are the most prevalent
HIV-1 genotypes circulating in Asia, were selected. The
results were sorted by their degree of conservation, and
ﬁltered to display siRNAs that satisfy at least one efﬁcacy
guideline. The off-target search results against human genes
are also shown. It is desirable to select an siRNA that has less
off-target hits.
To test the validity of siVirus, 35 siRNAs satisfying
the guideline by Ui-Tei et al. (6) were designed against the
conserved regions of HIV-1 genomes using siVirus and were
assayed for inhibition of viral replication. Among them, 31
siRNAs effectively inhibited HIV-1 replication by >80%
when each siRNA duplex was transfected at 5 nM (Y. Naito,
K. Ui-Tei, K. Saigo and Y. Takebe, unpublished data).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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